Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza

Expert Review of Respiratory Medicine

Volumn 4, Issue 2, 2010, Pages 171-177

  Wong, Jonathan P ^a   Christopher, Mary E ^a   Viswanathan, Satya ^a   Schnell, Glen ^a   Dai, Xiaojiang ^a   Van Loon, Donald ^a   Stephen, Eric R ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

Author keywords

Antiviral drugs; Efficacy; Influenza; Nasal spray; Respiratory tract; Review; Safety; Vaccines

Indexed keywords

ADAMANTANE DERIVATIVE; ANTIVIRUS AGENT; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; INFLUENZA VACCINE; LIPOSOME; OSELTAMIVIR; RIBAVIRIN; SWINE INFLUENZA VACCINE; THIOMERSAL; ZANAMIVIR;

AEROSOL; ANTIVIRAL RESISTANCE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TISSUE LEVEL; DRY POWDER; ENCAPSULATION; FEVER; HUMAN; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INJECTION SITE REACTION; NONHUMAN; NOSE CONGESTION; PANDEMIC INFLUENZA; REVIEW; RHINORRHEA; SEASONAL INFLUENZA; SINGLE DRUG DOSE; SWINE INFLUENZA; URTICARIA;

EID: 77951470798     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.15     Document Type: Review

References (43)

1. Sedyaningsih ER, Isfandari S, Setiawaty V et al. Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005-June 2006. J. Infect. Dis. 196(4), 522-527 (2007).
2. Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit. Care Med. DOI: 10.1097/ CCM.0b013e3181c92eeb (2009) (Epub ahead of print).
3. Kumar A, Zarychanski R, Pinto R et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 302(17), 1872-1879 (2009).
4. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N. Engl. J. Med. 361(7), 680-689 (2009).
5. de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12(10), 1203-1207 (2006).
6. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198(7), 962-970 (2008).
7. Davies A, Jones D, Bailey M et al. Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome. JAMA 302(17), 1888-1895 (2009).
8. Couch RB. Seasonal inactivated influenza virus vaccines. Vaccine 26(Suppl. 4), D5-D9 (2008).
9. McCarthy MW, Kockler DR. Trivalent intranasal influenza vaccine, live. Ann. Pharmacother. 38(12), 2086-2093 (2004).
10. Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr. Infect Dis. J. 23(2), 138-144 (2004).
11. McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176(10), 6333-6339 (2006).
12. Bleshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356, 685-696 (2007).
13. Piedra PA, Gaglani MJ, Riggs M et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 116(3), e397-e407 (2005).
14. Schechter R, Grether JK. Continuing increase in autism reported to Californias's developmental services system: mercury in retrograde. Arch. Gen. Psychiatry 65(1), 19-24 (2008).
15. McMahon AW, Iskander JK, Haber P, Braun MM, Ball R. Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosol-free or thimerosol-containing vaccine. Vaccine 26(3), 427-429 (2008).
16. Oxford JS. Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza Other Respi. Viruses 1(1), 27-34 (2007).
17. Smith JR, Ariano RE, Toovey S. The use of antiviral agents for the management of severe influenza. Crit. Care Med. DOI: 10.1097/CCM. 0b013e3181c85229 (2009) (Epub ahead of print).
18. De Clercq E. Antiviral agents active against influenza viruses. Nat. Rev. Drug Discov. 5(12), 1015-1025 (2006).
19. Bright RA, Medina MJ, Xu X et al. Incidence of adamantine resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366(9492), 1175-1181 (2005).
20. He G, Qiao J, Dong C, He C, Zhao L, Tian Y. Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res. 77(1), 72-76 (2008).
21. de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353(25), 2667-2672 (2005).
22. Boltz DA, Douangngeun B, Phommachanh P et al. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao PDR. J. Gen. Virol. DOI: 10.1099/ vir.0.017459-0 (2009) (Epub ahead of print).
23. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 53(10), 4433-4440 (2009).
24. Steain MC, Dwyer DE, Hurt AC et al. Detection of influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir using rolling circle amplification. Antiviral Res. 83(3), 242-248 (2009).
25. Poland GA, Jacobson RM, Ovsyannikova IG. Influenza virus resistance to antiviral agents: a plea for rational use. Clin. Infect. Dis. 48(9), 1254-1256 (2009).
26. Dharan NJ, Gubareva LV, Meyer JJ et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301(10), 1034-1041 (2009).
27. Scalera NM, Mossad SB. The first pandemic of the 21st century: a review of the 2009 pandemic variant influenza A (H1N1) virus. Postgrad. Med. 121(5), 43-47 (2009).
28. LaForce C, Man CY, Henderson FW et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin. Ther. 29(8), 1579-1590, discussion 1577-1578 (2007).
29. Kawai N, Ikematsu H, Iwaki N et al. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. J. Infect. 56(1), 51-57 (2008).
30. Kidd IM, Down J, Nastouli E et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 374(9694), 1036 (2009).
31. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83(20), 10366-10373 (2009).
32. Gilbert BE, Wilson SZ, Knight V et al. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob. Agents Chemother. 27(3), 309-313 (1985).
33. Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N. Engl. J. Med. 361(17), 1713-1714 (2009).
34. Gilbert BE, McLeay MT. Megaribavirin aerosol for the treatment of influenza A virus infections in mice. Antivir. Res. 78(3), 223-229 (2008).
35. Wong JP, Christopher ME, Salazar AM, Dale RM, Sun LQ, Wang M. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine 25(16), 3175-3178 (2007).
36. Wong JP, Christopher ME, Viswanathan S et al. Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses. Curr. Pharm. Des. 15(11), 1269-1274 (2009).
37. Wong JP, Christopher ME, Viswanathan S et al. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 27(25-26), 3481-3483 (2009).
38. Tuvim MJ, Evans SE, Clement CG, Dickey BF, Gilbert BE. Augmented lung inflammation protects against influenza A pneumonia. PLoS One 4(1), e4176 (2009).
39. Sindoni D, La Fauci V, Squeri R et al. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity. J. Prev. Med. Hyg. 50(2), 121-126 (2009).
40. Zhu FC, Wang H, Fang HH et al. A novel influenza A (H1N1) vaccine in various age groups. N. Engl. J. Med. 361(25), 2414-2423 (2009).
41. Quispe-Laime AM, Bracco JD, Barberio PA et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med. 36(1), 33-41 (2009).
42. Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respir. Viruses 3(4), 129-142 (2009).
43. Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev. Vaccines 8(12), 1681-1692 (2009).